Gilead Sciences Canada has taken home a Bronze Lion at Cannes for its creative HIV prevention campaign built around LGBTQIA+ community identity.
The campaign, titled Animal Attraction, was developed in partnership with Toronto-based agency The Local Collective for HIV prevention drug Descovy.
It earned Bronze in the use of humour category for branded product or service promotion at the prestigious Cannes Lions health and pharma awards.
The campaign drew on terms such as “bear,” “otter” and “wolf,” which are widely recognised within LGBTQIA+ culture as descriptors for different body types and identities.
Those terms were transformed into AI-generated illustrated animal characters depicting intimacy and connection, creating a visually distinctive and culturally resonant campaign.
The creative approach allowed the campaign to speak directly to its target audience while sidestepping the clinical tone that often dominates pharmaceutical advertising.
The Pharma Lions category attracted significant global competition this year, receiving a total of 236 entries from agencies and healthcare brands around the world.
Judges awarded seven Lions in total across the category, including one Grand Prix, one Gold, two Silver awards and three Bronze Lions.
Novartis and Fallon Minneapolis claimed the top prize, the Pharma Grand Prix, for their campaign titled Relax Your Tight End, a celebrity-led initiative encouraging men to seek prostate cancer screening.
Viatris’ Viagra Blue Brands secured Gold, while campaigns covering medication safety, HIV prevention, drug authenticity and seizure recognition picked up Silver and Bronze Lions respectively.
Cannes jurors were reported to have praised work that successfully paired humour and strong creative thinking with measurable real-world healthcare impact.
The Animal Attraction campaign reflects a broader industry shift toward culturally specific, community-led health communication rather than broad, generalised public health messaging.
For Gilead Sciences (GILD), the recognition adds creative credibility to its ongoing efforts to promote HIV prevention tools to audiences who face the greatest risk.